PQ 912

Drug Profile

PQ 912

Alternative Names: PQ-912

Latest Information Update: 29 May 2017

Price : $50

At a glance

  • Originator Probiodrug
  • Developer Covance; Probiodrug
  • Class Antidementias; Small molecules
  • Mechanism of Action Glutaminyl-peptide cyclotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Preclinical Inflammation

Most Recent Events

  • 16 May 2017 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Probiodrug
  • 12 May 2017 Efficacy data from a phase IIa trial in Alzheimer's disease released by Probiodrug
  • 09 Jan 2017 Probiodrug completes enrolment in the SAPHIR phase IIa trial for Alzheimer's disease in Belgium, Finland, France, Germany, Netherlands, Sweden and Spain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top